|

Germline Genetic Testing of the TP53 Gene

RECRUITINGSponsored by European Institute of Oncology
Actively Recruiting
SponsorEuropean Institute of Oncology
Started2026-01-29
Est. completion2026-07
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07419893

Summary

This is a retrospective, observational, single-center study designed as a cohort analysis. The study population will include consecutive patients referred for genetic counseling and TP53 germline genetic testing between 2004 and 2025 at the Division of Cancer Prevention and Genetics of the IEO. The primary endpoint is to determine the overall detection rate of Pathological Variants (PVs) in the TP53 gene among individuals referred to the institute and the differences between the groups.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* Have undergone at least one genetic counseling session at the Division of Cancer Prevention and Genetics of the IEO;
* Have undergone germline TP53 genetic testing, regardless of the referral criteria for counseling and/or testing or the approach used;
* Have provided written informed consent for participation in scientific research.

Exclusion Criteria:

* Absence of signed informed consent for participation in scientific research.

Conditions4

CancerMulti-Gene Transcriptional ProfilingTP53 Gene Germline Mutation CarrierTP53 Gene Mutation

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.